Multiple Myeloma
From the Journals
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
From the Journals
Quality of life decrement with salvage ASCT is short-lived
Salvage stem cell transplant in patients with multiple myeloma was linked to short-term, but not long-term, declines in quality of life, compared...
From the Journals
ASCO, CCO issue multiple myeloma treatment guidelines
An expert panel convened by ASCO and Cancer Care Ontario reviewed 124 recent studies to develop nearly 50 specific recommendations in transplant-...
Conference Coverage
Real world responses mirror TOURMALINE-MM1 data
GLASGOW – Median progression-free survival was more than 20 months in real-world patients who received triplet therapy, similar to findings from...
From the Journals
Combo could replace standard conditioning regimen for myeloma
The combination of busulfan plus melphalan produced superior progression-free survival but no overall survival advantage in the phase 3 trial.
News
FDA halts enrollment in trial of venetoclax for multiple myeloma
Increased risk of fatal infections
From the Journals
Oral triplet deemed effective in relapsed/refractory myeloma
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma....
From the Journals
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Selinexor hits FDA stumbling block
The Oncologic Drugs Advisory Committee expressed concern about the high rate of serious adverse events with the drug being developed to treat...
Conference Coverage
MRD negativity linked to survival in MM after auto-HCT
HOUSTON – MRD-negative status was prognostic for improved progression-free survival at all time points measured after transplant.